Loading
A phase 2 trial of Acalabrutinib and Venetoclax in chronic lymphocytic leukaemia, run by AstraZeneca, now recruiting.
Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab is a phase 2 interventional study registered as NCT07024706 by AstraZeneca, with 80 participants planned, started 2026-06-04 and due to reach its primary completion in 2029-05-01. Interventions recorded: Acalabrutinib and Venetoclax.
Shares Flatiron Health (Roche), BCL-2 inhibitors, Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Acalabrutinib, BCL-2 inhibitors, AbbVie (incl. ImmunoGen, Capstan), Venetoclax and the tag pipeline.
Shares BCL-2 inhibitors, AbbVie (incl. ImmunoGen, Capstan), Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Acalabrutinib, BCL-2 inhibitors, Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
Shares BCL-2 inhibitors, AbbVie (incl. ImmunoGen, Capstan), Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Acalabrutinib, Chronic lymphocytic leukaemia, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares Acalabrutinib, BCL-2 inhibitors, Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Acalabrutinib, Chronic lymphocytic leukaemia, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.